Recent advances on blinatumomab for acute lymphoblastic leukemia

Juanjuan Zhao1, Yongping Song1 and Delong Liu1,2*

Abstract
Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B- ALL. Blinatumomab, a bi-specific T cell engager, has been approved for patients with relapsed/refractory and minimal residual disease positive B-ALL. This review summarized data from recent clinical trials of blinatumomab for B-ALL treatment.

Keywords: Acute lymphoblastic leukemia, Blinatumomab, BiTE, Bispecific T cell engager

Background
Chemotherapy combined with targeted therapies and improved supportive care has enhanced complete remission (CR) rate of newly diagnosed B cell acute lymphoblastic leukemia (B-ALL) to 85–90%, and long-term survival rate to 40–45% [1]. However, about a third of standard-risk and two-thirds of high-risk patients experience recurrence [2, 3]. Relapsed and refractory (r/r) ALL has low rates of CR and poor long-term survival [2, 4, 5]. A retrospective analysis of 1706 r/r B-ALL patients without Philadelphia chromosome (Ph) and aged younger than 65 years showed that the CR rates were respectively 40%, 21%, 11% and 3-year survival rate were 11%, 5%, 4% for first, second, and ≥3rd salvage therapy, indicating progressively worse prognosis with each subsequent relapse [6]. Efforts are being made to improve the outcome of R/R ALL. First of all, to better define the disease status for guiding further therapy for consolidation and maintenance, minimal residual disease (MRD) is characterized more precisely with real-time quantitative PCR and multiparametric flow cytometry. MRD is defined as positive if blast cells are detected at above 0.01% level [7]. Next-generation sequencing (NGS) is increasingly used for monitoring MRD and better predicting early relapse [8, 9]. About 30–50% of adults and 10–20% of children with ALL achieved MRD-negative CR [10–14]. MRD is currently recognized as the most significant indicator for ALL relapse at all ages [15–17]. A meta-analysis of a total of 39 studies including 13,637 ALL individuals showed a significant correlation between negative MRD and 10-year EFS (HR = 0.23 for pediatric subjects and = 0.28 for adult subjects) and OS (HR = 0.28 for pediatric subjects and = 0.28 for adult subjects) [18]. Secondly, to add targeted agents such as tyrosine kinase inhibitors and CD20 antibodies to chemotherapy regimens when appropriate biomarker targets are present [19–26]. CD19 is expressed in normal and malignant B cells [27–30]. Engineered T cells with CD19-targeted chimeric antigen receptors (CAR T) are widely studied for R/R ALL [31–33]. Recently, a CD19 × CD3 bispecific T cell engager (BiTE), blinatumomab (Blincyto, Amgen), has been developed [34]. Blinatumomab contains CD3 and CD19 single-chain variable regions linked by a glycine-serine linker. It binds selectively to CD3 expressing T cells and CD19 expressing B cells, leading to the formation of immune synapses between T cells and B cells [35, 36]. This redirects unstimulated cytotoxic T cells to specifically target and lyse CD19-positive B cells, both malignant and normal B cells. The blinatumomab BiTE single-chain antibody fragment has a molecular weight of 54 kDa. Blinatumomab is administered through...
continuous IV infusion for 4 weeks followed by a 2-week interval [37–39]. Similar to CAR T therapy, cytokine release syndrome (CRS) and neurotoxicity are the two major adverse events associated with blinatumomab therapy [38, 40, 41]. Blinatumomab achieved accelerated US Food and Drug Administration (FDA) approval for R/R ALL (Fig. 1) [42, 43]. Blinatumomab has been approved for treatment of R/R ALL in 53 countries [44]. This review summarized recent updates on clinical trials of blinatumomab for B-ALL.

**Blinatumomab clinical trials for ALL**

**Blinatumomab for R/R ALL**

In a phase 2 clinical trial of blinatumomab for R/R B-ALL, a total of 36 patients were enrolled. The CR/CRh rate was 69% (25/36) after the first two cycles. Among the responders, 88% (22/25) achieved a molecular remission. The MRD-negative response rate was 69%. It was noticed that the quality of response was worse in second or greater relapse. With a median follow-up of 9.7 months (m), the median relapse-free survival (RFS) was 7.6 m [45]. Since CD19+ normal B cells were also affected, lymphopenia was the most frequent severe adverse event (SAE). After cessation of therapy, lymphopenia became reversible. After longer follow-up (median 33 months), 80% MRD-negative response rate was reported [46]. This study with long-lasting complete remission in R/R B-lineage ALL patients laid foundation for further expanded clinical investigation.

In a separate large, multicenter, phase II trial (MT103-211, NCT01466179), 189 adult patients with Ph-negative R/R B cell ALL were enrolled to further assess the clinical activity of blinatumomab [38]. Patients who relapsed within 12 months after allogeneic hematopoietic stem cell transplantation (allo-HSCT) were included. Step-wise dose ramp-up of blinatumomab was used to minimize initial CRS and neurotoxicities. Blinatumomab was infused at 9 µg/day for the first week, followed by 28 µg/day for the remaining 3 weeks. Treatment was cycled every 6 weeks. The results showed that CR/CRh was achieved in 43% of the patients (33% CR + 10% CRh) after the first two cycles. The median RFS was 5.9 m (median follow-up of 8.9 m), and the median OS was 6.1 m (median follow-up of 9.8 m) [38]. Among the 81 patients who achieved CR/CRh, 40% proceeded to allo-HSCT. Febrile neutropenia and anemia were common adverse events (AE). Severe CRS events including hypoxia, high fever and hypotension were reported in 3 patients. Tremors, seizure and mental status changes were reported as common neurotoxicity. It was noticed that 20% of the patients who received blinatumomab in this study were still alive after 2 years. Therefore, the data from this study were compared with historical data with long-term outcome from 1139 Ph negative B-ALL patients [47]. The long-term survival was estimated [47]. The estimated long-term (60 m) OS rate (12.4% vs 5.4%) and median OS (76.1 vs 38.6 m) of this clinical trial were significantly better than those from historical group before blinatumomab era. Even though these were not the results from a randomized study, these findings implied that blinatumomab has the potential to be better than salvage chemotherapy.

![Fig. 1](image_url) The approval timeline of blinatumomab by US FDA. r/r refractory/relapsed.
To confirm the efficacy of blinatumomab for R/R ALL, a phase III randomized trial (the TOWER trial, NCT 02013167) was done to compare blinatumomab versus salvage chemotherapy. This study enrolled 405 patients. The patients were randomized in a 2:1 ratio. 271 patients received blinatumomab, 124 patients received salvage chemotherapy. Compared with salvage chemotherapy, blinatumomab monotherapy had better OS (7.7 m vs 4.0 m, P = 0.01), CR rate (34% vs 16% in 12 weeks, P < 0.001) and EFS rate (31% vs 12% at 6 m, P < 0.001) in r/r B-ALL patients [48].

### Blinatumomab for MRD+ ALL

MRD remains measurable in 30 to 50% of adult ALL patients in hematologic CR after chemotherapy. It has been well established that positive MRD in ALL is associated with higher relapse rate and poor OS [17]. Allo-HSCT was reported to increase the 5-year RFS of MRD+ ALL from 11 to 44% [12].

An analysis of 20 evaluable ALL patients treated with blinatumomab revealed negative MRD in 16 of them, suggesting deep response in 80% patients [49]. The final analysis of this study reported a median follow-up of 50.8 months. Half of the 20 patients (50%) remained in CR 5 years after the initial treatment [50].

Blinatumomab was examined in MRD+B-ALL patients in a multicenter open-label single-arm phase 2 study in patients with MRD+ (≥ 10−3) B-ALL who were in CR1 or CR 2/3. Among the 116 patients enrolled, 113 patients who received blinatumomab were evaluable. Among these, 78% were found to have negative MRD (MRD responders) after 1 cycle of blinatumomab. Compared with MRD non-responders, MRD responders had longer RFS (23.6 vs 5.7 months; P = 0.002) and OS (38.9 vs 12.5 months; P = 0.002). This study confirmed that blinatumomab is effective in eliminating MRD [51]. After a minimum follow-up of 3 years (median 53.1 m), OS has reached a plateau and the median survival has not been reached among the patients with a complete MRD response [52]. Blinatumomab became the first FDA-approved treatment for MRD+B-ALL in 2018 [53].

### Blinatumomab in combination therapy for ALL

**Blinatumomab + tyrosine kinase inhibitors**

Tyrosine kinase inhibitors (TKI) are playing a major role in the therapy for Ph+ ALL [24, 26, 55, 56]. TKIs in combination with blinatumomab are being evaluated for Ph+ ALL [57]. Blinatumomab + ponatinib was used in 15 patients with relapsed Ph+ ALL [58]. In this retrospective analysis, ponatinib was given daily whereas blinatumomab was given a median of 3 cycles. 14 of the 15 patients achieved cytogenetic remission, with molecular CR in 12 patients. Two patients had CNS relapse while in molecular remission. The follow-up was short (median 8.5 months). A prospective trial is underway to evaluate the chemotherapy-free regimen (NCT03263572).

A group from the Memorial Sloan-Kettering Cancer Center reported a retrospective analysis of 11 patients who received blinatumomab plus one of the TKIs (ponatinib, dasatinib or nilotinib) [59]. Seven of the 11 MRD+ patients became MRD negative. The median follow-up was 7.7 months (range 3.2–16.0 months). Grade 1 CRS was seen in three patients and no patient had neurotoxicity. The blinatumomab and ponatinib combination was reported to have higher risk of liver enzyme abnormality.

Overall, the combination of blinatumomab with TKI was well tolerated. The chemotherapy-free regimen appears to be promising to serve as a bridge therapy prior to allo-HSCT.

**Blinatumomab + immune checkpoint inhibitors**

Recently, a multi-center phase I dose-escalation study was initiated to evaluate the combination of blinatumomab with nivolumab and ipilimumab for R/R CD19+ ALL patients [60]. The patients were scheduled to receive up to 5 cycles of blinatumomab and 1 year of nivolumab/ipilimumab. The first part of the study was to evaluate the safety of combining blinatumomab with nivolumab. Once the dose is established, ipilimumab dose escalation will be added. A preliminary report enrolled 8 adults at dose level I. Five patients were evaluable. Common AEs included liver enzyme elevation and chemical pancreatitis. DLT was reported to be Infusion-related reactions to nivolumab. Four out of five evaluable patients achieved CR with -MRD. It appears that the blinatumomab/nivolumab combination in R/R ALL is well tolerated. The next phase of the study to add ipilimumab is ongoing.

### Blinatumomab + chemotherapy

Hyper-CVAD is a commonly used regimen for ALL therapy [61–66]. In an attempt to improve response rate and quality, blinatumomab was added to hyper-CVAD
regimen in a phase 2 study [67]. After induction therapy with 4 cycles of Hyper-CVAD, blinatumomab was given as consolidation therapy for a total of 4 cycles. Monoclonal antibodies against CD20 were added for those patients with CD20+ ALL. In this study, blinatumomab was also added to the maintenance phase on cycles 4, 8 and 12 [57]. POMP (6-mercaptopurine, vincristine, methotrexate, prednisone) regimen was used for maintenance on cycles 1–3, 5–7, 9–11 and 13–15. A preliminary report of 17 patients revealed an ORR of 100%. MRD negativity was 93%. Among 14 evaluable patients, 9 patients have completed hyper-CVAD plus blinatumomab sequential therapy and entered maintenance phase. With a median follow-up of 14 months (range, 3–20 months) at the time of the report, the rates of OS and CR were 94% and 93%, respectively. A transient grade 3 CRS event was reported in one patient, and one had grade 3 neurotoxicity. These two patients both recovered after interruption of blinatumomab and prompt steroid therapy. Therefore, the sequential combination of Hyper-CVAD and blinatumomab was well tolerated as frontline regimen in B-ALL. This study attempts to reduce Hyper-CVAD chemotherapy to 4 cycles from conventional 8 cycles by adding 4 cycles of blinatumomab. This study also added blinatumomab in the maintenance phase so that the POMP maintenance time is reduced from usually 3 years to 12 months. In conclusion, this study may lead to reduction of chemotherapy toxicity and duration of maintenance therapy.

**miniHCVD + inotuzumab + blinatumomab**

Inotuzumab ozogamicin (INO) is CD22 antibody–drug conjugate which has been approved for R/R ALL [61, 68–77]. Both INO and blinatumomab (blina) were superior as single agent to salvage chemotherapies in R/R ALL [37, 74]. Blinatumomab is being studied in combination with the miniHCVD–INO regimen for newly diagnosed ALL patients [71, 78–80]. Rituximab was added in patients with CD20 expression ≥20%. There were three phases in the therapy regimen: intensification, consolidation and maintenance. In the intensification phase, 4 cycles of miniHCVD was followed by 4 cycles of INO. Two lower doses of INO was given in each cycle. 4 cycles of blinatumomab was given in the consolidation phase. In the maintenance phase, 4 more cycles of blinatumomab were given on month 4, 8, 12 and 16. The POMP regimen was given in the maintenance as described above for a total of 12 cycles. Addition of blinatumomab makes it possible to reduce POMP maintenance cycles from 3 years to 12 months.

### Table 1 Ongoing clinical trials of combined treatment with blinatumomab for B-ALL

| NCT Number      | Patients                              | Treatment                                      | Phase  |
|-----------------|---------------------------------------|------------------------------------------------|--------|
| NCT02877303     | Newly diagnosed B-ALL                 | Blinatumomab + hyper-CVAD                     | Phase 2|
| NCT03367299     | Untreated Ph− CD19+ B-ALL             | Blinatumomab + chemotherapy                   | Phase 2|
| NCT03480438     | Older newly diagnosed Ph/BCR-ABL- CD19+ B-ALL | Blinatumomab + chemotherapy                  | Phase 2|
| NCT03518112     | Ph− R/R B-ALL                         | Blinatumomab + chemotherapy                   | Phase 2|
| NCT03914625     | Newly diagnosed standard risk or down syndrome B-ALL and localized B-Lly | Blinatumomab + chemotherapy                  | Phase 3|
| NCT02143414     | Older newly diagnosed Ph− B-ALL       | Blinatumomab + chemotherapy                   | Phase 2|
| NCT03263572     | Ph/BCR-ABL+ B-ALL                     | Blinatumomab + ponatinib + cytarabine + Methotrexate | Phase 2|
| NCT03147612     | R/R Ph+/BCR-ABL+ B-ALL               | Blinatumomab + ponatinib + chemotherapy       | Phase 2|
| NCT02744768     | Newly diagnosed adult Ph+B-ALL        | Blinatumomab + dasatinib                      | Phase 2|
| NCT03605589     | R/R B-ALL                             | Blinatumomab + pembrolizumab                  | Phase 1|
| NCT03160079     | R/R B-ALL                             | Blinatumomab + pembrolizumab                  | Phase 1/2|
| NCT03512405     | R/R B-ALL                             | Blinatumomab + pembrolizumab                  | Phase 1/2|
| NCT02879695     | R/R B-ALL                             | Blinatumomab + nivolumab with or without ipilimumab | Phase 1|
| NCT02997761     | R/R B-ALL                             | Blinatumomab + ibritunib                      | Phase 2|
| NCT03739814     | Newly diagnosed or R/R CD22+ B-ALL    | Blinatumomab + inotuzumab ozogamicin          | Phase 2|
| NCT03751709     | R/R CD19+ B-ALL                       | Blinatumomab + HMCT                           | Phase 1|
| NCT03849651     | Hematologic malignancies              | Blinatumomab + DLI                            | Phase 2|
| NCT03982992     | B-ALL with MC or MRD-positive after allo-HSCT | Blinatumomab + DLI                            | Phase 2|
| NCT02790515     | R/R hematologic malignancies          | Blinatumomab + haploidentical HCT             | Phase 2|

R/R relapsed/refractory; B-ALL B-cell acute lymphoblastic leukemia; HMCT HLA-mismatched cellular therapy; BM bone marrow; B-Lly B-Lymphoblastic lymphoma; HCT hematopoietic cell transplant; DLI donor lymphocyte infusion; MC mixed chimerism; MRD minimal residual disease; allo-HSCT allogeneic hematopoietic stem cell transplantation
In a recent report, 58 newly diagnosed elderly B-ALL patients were enrolled [79]. Fifty-four patients were evaluable for morphological responses and 57 patients were evaluable for MRD status. Both ORR and MRD negativity were 95%. Sinus occlusive syndrome (SOS) was known to be associated with INO. SOS was seen in 8–11% of the patients. With a median follow-up of 28 months, the 3-year OS rate was estimated to be 54%. Therefore, it appears that adding blinatumomab to the miniHCVD + INO regimen was safe and effective in elderly patients with newly diagnosed ALL.

The miniHCVD + INO +/- blina regimen is also being studied in R/R ALL [78, 80]. In a recent report, 17 out of 84 patients received miniHCVD + INO + blina [80]. The SOS rate was markedly reduced to 0% from 15% after INO was split to two lower doses each cycle. Although the schedules are complicated, this low-intensity miniHCVD + INO + blina regimen appears to be well tolerated and effective in R/R ALL patients. The long interval between INO and allo-HSCT as well as split-dose INO has markedly reduced the SOS risk.

Conclusion and future perspectives
Blinatumomab has been approved for patients with R/R B-ALL and MRD + B-ALL. Blinatumomab is being studied for use in frontline therapy of newly diagnosed B-ALL. Adding blinatumomab to the low intensity miniHCVD + INO regimen in the consolidation and maintenance phases appears to be promising. The mechanisms of blinatumomab resistance and predictive biomarkers for response remain uncertain [81]. Blinatumomab in maintenance therapy appears to be promising to minimize chemotherapy and reduce therapy duration. More BiTE antibodies are coming to clinical applications [82, 83]. New regimens incorporating blinatumomab may lead to new therapy modalities for ALL. Combination of blinatumomab with TKIs or with immune checkpoint inhibitors are ongoing and may result in chemotherapy-free regimens for ALL (Table 1).

Abbreviations
CR: complete remission; B-ALL: B cell acute lymphoblastic leukemia; r/r: relapsed and refractory; SOC: standard of care; OS: overall survival; m: months; MRD: minimal residual disease; FDA: Food and Drug Administration; AEs: adverse effects; CrH: CR with partial hematologic recovery; allo-HSCT: allogeneic hematopoietic stem cell transplantation; CL: clearance; cIVi: continuous intravenous infusion;Css: steady-state concentrations; NES: neurologic events; CRS: cytokine release syndrome; TKIs: tyrosine kinase inhibitors; DLI: donor lymphocyte infusions.

Acknowledgements
DL is a Professor of Medicine at the New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA.

Authors’ contributions
DL and JZ designed the study and drafted the manuscript. All authors participated in the revision of the manuscript. All authors read and approved the final manuscript.

Funding
The study is partly supported by the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Availability of data and materials
The material supporting the conclusion of this review has been included within the article.

Ethics approval and consent to participate
This is not applicable for this review.

Consent for publication
This is not applicable for this review.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China. 2 Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA.

Received: 7 October 2019   Accepted: 31 October 2019
Published online: 06 November 2019

References
1. Hoelzer D, Bassan R, Dombrert H, Fielding A, Ribera JM, Buske C, Committee EG. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v59–82.
2. Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobb G, Kreuzer KA, Leimer L, Reichle A, Schlaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viajrod A, Wendelin K, Freund M, Hoelzer D, German Multicenter Study Group for Adult Acute Lymphoblastic L. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–41.
3. Frey NV, Lugger SM. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2015;126(5):589–96.
4. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O’Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010;116(24):5568–74.
5. Oriol A, Vives S, Hernandez-Rivas JM, Torno M, Heras I, Rivas C, Bethencourt C, Moscardo F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM, Programa Espanol de Tratamiento en Hematologia G. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95(4):589–96.
6. Gokbuget N, Dombrert H, Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Dubbek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsch M, Martinelli G, Morgades M, O’Brien S, Rowe J, Stiegmaier J, Wadleigh M, Kantarjian H. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524–33.
7. van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4000.
8. Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. J Hematol Oncol. 2018;11(1):105.

9. Jastaniah W, Elnamawy K, Abellana AA, Elgamal AM, Alkassar A, Daghastani M, Felmans S. Early vs late MRD response and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia. Exp Hematol Oncol. 2018;7(1):29.

10. van Dongen JJ, Serui T, Panzer-Gramatry ER, Bondi A, Pongers-Willemsen MJ, Coon R, Stolz F, Schrappe M, Masera G, Kamps WA, Gahner H, van Wering ER, Ludwig WD, Basso G, de Brujin HA, Hettlinger K, van den Berg A, Hop WC, Riehm H, Bartram CR. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731–8.

11. Eckert C, Bondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358(9289):1239–41.

12. Gökbuget N, Kneba M, Raft T, Trautmann H, Bartram CR, Arnold R, Fietkau R, Freund M, Ganser A, Ludwig WD, Maschmeyer G, Rieder H, Schwartz S, Serve H, Thiel E, Bruggemann M, Hoelzer D, German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1866–76.

13. Bassan R, Spollini O, Oldani E, Intermezoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Teruzzi E, Fabris P, Cassibba V, Lambertenghi-Delliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Cicin F, Bernardi M, Gallamini A, Matti D, Di Bona E, Romani C, Scattolin AM, Barbu T, Rambaldi A. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukaemia (ALL). Blood. 2009;113(18):4153–62.

14. Holowicki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Skotnicki AB, Jedrzejczak WW, Mysliwiec M, Czyz A, Balana-Nowak A, Kołodziejska H, Warzocha K, Lange A, Hellmann A. Status of minimal residual disease after induction therapy predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008;142(2):227–37.

15. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Wiswanatha D, Willman CL, Winick N, Camitta BM, Children’s Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;112(11):5477–85.

16. Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, Thomas J, Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Beran A, Brad Pitt J, van den Berg A, Hop WC, Riehm H, Bartram CR. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731–8.

17. Thomas DA, Kadiviec F, Sordes C, O’Brien S, Gills FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jebara M, Beran A, Beran M, Verstovsek S, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104(16):1624–30.

18. Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce SA, Ganser A, Keating MJ, Cortes J, Kantarjian H. Chemomunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569–80.

19. Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce SA, Ganser A, Keating MJ, Cortes J, Kantarjian H. Chemomunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukaemia. J Clin Oncol. 2010;28(24):3880–9.

20. Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Koya RV, Rousset P, Gambacorti-Passerini C. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11(1):143.

21. Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and young adults for St Jude Children’s Research Hospital. Blood. 2015;125(24):3702–10.

22. Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):84.

23. Carter RH, Myers R. Germline cell structure and function: lessons from CD19. Semin Immunol. 2008;20(1):43–8.

24. Carter RH, Wang Y, Brooks S. Role of CD19 signal transduction in B cell lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36.

25. Wang J, Hu Y, Huang H. Advances of CD19-directed chimeric antigen receptor T-cell therapy. Stem Cell Investig. 2018;5:44.

26. Wei G, Ding L, Wang J, Hu Y, Huang H. Improvements of CD19-directed chimeric antigen receptor-modified T cells in refractory/refractory acute lymphoblastic lymphoma. Exp Hematol Oncol. 2017;6(1):10.

27. Zhang C, Liu J, Zheng JF, Zhang X. Engineering CART cells. Biomark Res. 2017;5(1):22.

28. Nagorsen D, Baueerle PA. Immunomodulatory therapy of cancer with T-cell engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255–60.

29. Loffler A, Kufer P, Lutterbuser Z, Rett F, Daniel PT, Schwennchenbecher JM, Riethmuller G, Dorken B, Bargou RC. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2008–13.

30. Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphocytic leukaemia. J Hematol Oncol. 2015;8(1):104.

31. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, Wei A, Dombert H, Foà R, Bassan A, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horsz H-A, Bruggemann M, Klapper W, Wood BL, Fleshman A, Nagorsen D, Holland C, Zimmerman T, Topp MS. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukaemia. N Engl J Med. 2017;376(9):836–47.

32. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, Dombert H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera J-M, Rambaldi A, Schiller G, Bruggemann M, Horsz H-A, Holland C, Ji A, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM, Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(11):57–66.

33. Nägele V, Katzer A, Zugmaier G, Holland C, Hijazi V, Topp MS, Gökbuget N, Baueerle PA, Kufer P, Wolf A, Klinger M. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp Hematol Oncol. 2017;6(1):14.
40. Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2019;11(1):35.

41. Neeleman SS, Tummala S, Kebraii P, Wiarda W, Locke FL, Lin Y, Jain N, Daver N, Gilbus AM, Adkins S, Rezvani K, Huw P, Shappi EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ALL. Nat Rev Clin Oncol. 2018;15(4):218.

42. Valkharia P, Nardone B, Budris W, Hoszhiki H, Frankfort D, West DP. Blinatumomab and panitumab: an analysis of a FAERS, EU Vigilance, and a large urban U.S. patient population data. Leuk Lymphoma. 2018;59(7):1759–61.

43. Przepiorka D, Kebriaei P, Deisseroth A, Yancey CL, Candau-Charon R, Chiu HJ, Gehrer BJ, Gomez-Broughton C, Kane RC, Kishner S, Mehrnitz N, Rick TK, Schmiedl D, Song P, Zhao P, Zhou Q, Farrell AT, Pazzur R. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035–9.

44. Stein A, Franklin JL, Chu VA, Arrindell W, Wright J, Parson M, Amouzadeh HR, Choudhry J, Joseph G. Benefit-risk assessment of blinatumomab in the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Drug Saf. 2018;42(5):587–601.

45. Topp MS, Golubnct D, Zugmaier G, Klapper P, Stelljes M, Neumann S, Viardot A, Marks R, Dierich H, Faul C, Recheile A, Horst HA, Bruggermann M, Wessiepe D, Holland C, Alekar S, Mergen N, Eisehle H, Hoelzer D, Bargou R. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40.

46. Topp MS, Golubnct D, Zugmaier G, Degenhard H, Goebeler M, Klinger M, Neumann S, Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Bruggemann M, Naihor GA, Nagorsen D, Schmidt M, Eisehle H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou R. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(20):1585–7.

47. Barlev A, Lin VW, Katz A, Hu K, Cong Z, Fader B, Barber B. Estimating long-term survival of adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia treated with blinatumomab using historical data. Adv Ther. 2017;34(1):148–55.

48. Kantarjian H, Stein A, Golubnct D, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sazn MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klappper W, Wood BI, Fleshman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47.

49. Topp MS, Kufer P, Golubnct D, Goebeler M, Klinger M, Neumann S, Horst HA, Raft T, Viardot A, Schmid M, Stelljes M, Schacht M, Degenhard E, Kohne-Volland R, Bruggemann M, Ottmann OG, Burmeister T, Baueere PA, Nagorsen D, Schmidt M, Eisehle H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou R. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(20):1585–7.

50. Arslan O, Kantarjian H, Omuro A, Bone Marrow Transplantation Study Group. Mitigation of bispecific T cell-engager-induced toxicities: a phase 1 study. J Hematol Oncol. 2019;12(1):15.

51. Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2019;12(1):35.

52. Goekbuget N, Dombret H, Zugmaier G, Bonifacio M, Graux C, Faul C, Naihorn GA, Nagorsen D, Schmidt M, Eisehle H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou R. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(20):1585–7.

53. Barlev A, Lin VW, Katz A, Hu K, Cong Z, Fader B, Barber B. Estimating long-term survival of adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia treated with blinatumomab using historical data. Adv Ther. 2017;34(1):148–55.

54. Kantarjian H, Stein A, Golubnct D, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sazn MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klappper W, Wood BI, Fleshman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47.

55. Topp MS, Kufer P, Golubnct D, Goebeler M, Klinger M, Neumann S, Horst HA, Raft T, Viardot A, Schmid M, Stelljes M, Schacht M, Degenhard E, Kohne-Volland R, Bruggemann M, Ottmann OG, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baueere PA, Kneba M, Eisehle H, Riethmüller G, Hoelzer D, Kufer P, Bargou R. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(20):1585–7.

56. Barlev A, Lin VW, Katz A, Hu K, Cong Z, Barber B. Estimating long-term survival of adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia treated with blinatumomab using historical data. Adv Ther. 2017;34(1):148–55.

57. Liu D, Zhao J, Song Y, Luo X, Yang T. Clinical trial update on bispecific anti-B-cell antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol. 2019;12(1):15.

58. Cooter MA, Thomas X, Huguet F, Berthon C, Simand C, Hicher Y, Hanaut M, Chevallier P. Blinatumomab plus ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(11):1547–55.

59. Liu D, Zhao J, Song Y, Luo X, Yang T. Clinical trial update on bispecific anti-B-cell antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol. 2019;12(1):15.

60. Webster J, Luzkin MR, Prince GT, DeZern AE, DeAngelo DJ, Murphy S, Blackford A, Sharon E, Streicher H, Luzkin L, Gojo I. Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed/refractory (R/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): preliminary results of a phase 1 study. Blood. 2018;132(Suppl 1):1401.

61. Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–801.

62. Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547–61.

63. Ravandi F, O’Brien S, Thomas D, Faderi S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(2):2070–7.
68. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK. Antibody-targeted chemotherapy with CMC-S44: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(3):1807–14.

69. DiJoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-S44) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21:2240.

70. Eerhoo-Orbea J, Sicard T, Cui H, Mazhab-Jafari MT, Benlekbir S, Guarné A, Rubinstein JL, Julien J-P. Molecular basis of human CD22 function and therapeutic targeting. Nat Commun. 2017;8(1):764.

71. Kantarjian H, Jabbour E. Incorporating immunotherapy into the treatment strategies of b-cell adult acute lymphoblastic leukemia: the role of blinatumomab and inotuzumab ozogamicin. Am Soc Clin Oncol Educ Book. 2018;38:574–8.

72. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebrsiea P, Ryetting M, York S, Ravandi F, Garris R, Faderl S, Cortes J, Fayad L, Tarrahi R, Wang SA, Champlin R, Advani A, O’Brien S. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–11.

73. Kantarjian H, Thomas D, Jorgensen J, Kebrsiea P, Jabbour E, Ryetting M, York S, Ravandi F, Garris R, Faderl S, Cortes J, Champlin R, O’Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36.

74. Kantarjian HM, DeAngelis DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O’Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandenbroucke E, Advani AS. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.

75. Kantarjian HM, Su Y, Jabbour EJ, Bhattacharya H, Yan E, Cappelleri JC, Marks Di. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151–60.

76. Abla A, Abla R, Liu D. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019;7(1):9.

77. Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12(1):94.

78. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebrsiea P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O’Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124(20):4044–55.

79. Short NJ, Jabbour EJ, Ravandi F, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Khoury JD, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz M, Borthakur G, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnás P, Jacob J, Garris RE, Brien SM, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-cvd, with or without blinatumomab, for newly diagnosed older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: results from a phase II study. Blood. 2018;122(Suppl 1):36.

80. Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Kebrsiea P, Huang X, Ryetting ME, Jain N, Konopleva MY, Garcia-Manero G, Champlin RE, Kadia TM, Cortes JE, Estrov ZE, Takahashi K, Mace M, Khouri M, Nasnás P, Jacob J, Garris RE, Jabbour EJ. Sequential combination of low-intensity chemotherapy (mini-hyper-CVD) plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed/refractory philadelphia chromosome-negative acute lymphoblastic leukemia (ALL): a phase 2 trial. Blood. 2018;132(Suppl 1):S53.

81. Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4.

82. Yu S, Liu Q, Han X, Qin S, Zhao W, Li A, Wu H. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol. 2017;6(1):31.

83. Zhang X, Yang Y, Fan D, Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. Exp Hematol Oncol. 2017;6(1):12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.